REG - GSK PLC - Director/PDMR Shareholding
21/02/2025 07:15
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250221:nRSU9388Xa&default-theme=true
RNS Number : 9388X GSK PLC 20 February 2025
GSK plc (the 'Company')
2025 Performance Share Plan Award
2025 Performance Share Plan Award
On 17 February 2025, the Company granted conditional share awards to the
Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons
Closely Associated ('PCAs') listed below under the GlaxoSmithKline 2017
Performance Share Plan ('the Plan'). The Plan was approved by shareholders on
4 May 2017 and allows a performance-related opportunity in the form of
conditional awards to be granted to senior executives in the Group, including
the Executive Directors and other PDMRs.
Under the terms of the Plan, conditional awards are granted over a specific
number of Ordinary Shares or American Depositary Shares ('ADS'), and the
percentage of awards that ultimately vests is dependent on the level of
achievement against performance targets set by the Remuneration Committee.
The performance period for the awards is the three financial years from 1
January 2025 to 31 December 2027.
The performance measures applicable for the 2025 Plan award will be the
subject of a separate release and included in the Company's 2024 Annual
Report.
Notes
1. To the extent that each element of a conditional award does not vest at
the end of the three-year performance period, it will lapse.
2. The PDMRs in the transaction notifications below were each granted a
conditional award under the terms of the GlaxoSmithKline 2017 Performance
Share Plan. Awards granted are of Ordinary Shares or ADS.
3. Dividends will accrue on the conditional award of Ordinary Shares or
ADS during the performance period but will only vest to the extent that the
awards themselves vest at the end of the performance period. These dividends
are not included in the figures below.
4. For Executive Directors, the award is subject to an additional vesting
period of two years (the 'Holding Period') from the normal vesting date, i.e.
five years in total. During the additional Holding Period, the relevant
Ordinary Shares or ADS would only be forfeited in the event that the
Executive Director was terminated for cause, and the Ordinary Shares or ADS
will continue to carry rights to dividend equivalents.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 573,313
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Julie Brown
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 285,072
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 112,442
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 194,320
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 81,690
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 298,713
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADS')
ISIN: US37733W2044
b) Nature of the transaction A conditional award of ADS under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$36.17 69,302
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 208,247
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 218,217
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Philip Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 96,047
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, GSK Global Health
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 198,094
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Anthony Wood (Tony)
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.35 276,842
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction A conditional award of Ordinary Shares under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.195 11,800
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-02-17
f) Place of the transaction N/A
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSEIFASEISESERecent news on GSK
See all newsREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Nucala MATINEE data in COPD published in NEJM
Announcement